off-label use of glp-1 agonists for obesity in 2016 Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Five Unexpected New Uses for

Increased Energy Expenditure: GLP-1 RAs may activate sympathetic pathways in the hypothalamus (specifically the dorsomedial and ventromedial nuclei) that increase thermogenic activity in brown adipose tissue (BAT), contributing to increased energy expenditure and weight loss

Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors expert forum

(2024) examined 9,465 patients with type 2 diabetes undergoing THA, comparing 1,653 semaglutide users to a matched control group of 7,812 non-users

Impact of pharmacist intervention to improve medication access for patients with diabetes

5 Gharagozloo, M, Galleguillos D, Jank L, et al

In a recent study published in the JAMA Network Open , a group of researchers evaluated the impact of exercise, glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide, and their combination on bone health at the hip, spine, and forearm following diet-induced weight loss in adults with obesity